Seelos Therapeutics Inc (NASDAQ: SEEL) stock fell -2.06% on Monday to $0.12 against a previous-day closing price of $0.13. With 3.12 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1325 whereas the lowest price it dropped to was $0.1217. The 52-week range on SEEL shows that it touched its highest point at $1.66 and its lowest point at $0.11 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at 2.07.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SEEL was up-trending over the past week, with a rise of 0.41%, but this was down by -37.20% over a month. Three-month performance dropped to -88.84% while six-month performance fell -87.54%. The stock lost -85.32% in the past year, while it has lost -81.75% so far this year. A look at the trailing 12-month EPS for SEEL yields -0.45 with Next year EPS estimates of -0.31. For the next quarter, that number is -0.12. This implies an EPS growth rate of 51.28% for this year and 7.79% for next year.
Float and Shares Shorts:
At present, 161.38 million SEEL shares are outstanding with a float of 157.88 million shares on hand for trading. On Oct 30, 2023, short shares totaled 8.32 million, which was 5.57% higher than short shares on Sep 28, 2023. In addition to Dr. Raj Mehra J.D., Ph.D. as the firm’s Founder, Chairman, CEO & President, Mr. Michael J. Golembiewski serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 20.36% of SEEL’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.76% of SEEL, in contrast to 2.17% held by mutual funds. Shares owned by individuals account for 19.75%. As the largest shareholder in SEEL with 7.89% of the stake, Sabby Management LLC holds 11,792,861 shares worth 11,792,861. A second-largest stockholder of SEEL, Tontine Associates LLC, holds 6,744,585 shares, controlling over 4.51% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in SEEL, holding 5,137,484 shares or 3.44% stake. With a 2.25% stake in SEEL, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 3,356,797 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.09% of SEEL stock, is the second-largest Mutual Fund holder. It holds 1,634,216 shares valued at 0.3 million. AdvisorShares Psychedelics ETF holds 0.78% of the stake in SEEL, owning 1,170,850 shares worth 0.22 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SEEL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SEEL analysts setting a high price target of $4.00 and a low target of $4.00, the average target price over the next 12 months is $4.00. Based on these targets, SEEL could surge 3233.33% to reach the target high and rise by 3233.33% to reach the target low. Reaching the average price target will result in a growth of 3233.33% from current levels.
Summary of Insider Activity:
Insiders traded SEEL stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 12,500 shares were bought while 0 shares were sold. The number of buy transactions has increased to 2 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 25,000 while 0 shares were sold.
